Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review

Jiamin Xu; Zhongming Wang

doi:10.3389/fonc.2023.1285593

Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review

Front Oncol. 2023 Dec 5:13:1285593. doi: 10.3389/fonc.2023.1285593. eCollection 2023.

Authors

Jiamin Xu¹, Zhongming Wang²

Affiliations

¹ School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
² Department of Oncology and Radiotherapy, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.

Abstract

Targeted drug therapy plays an important role in the clinical application of non-small cell lung cancer, especially adenocarcinoma. However, for patients with advanced disease, drug resistance after targeted therapy, unclear target, and other reasons that cannot or do not want surgery, the combination of chemotherapy, radiotherapy, immunity, etc. is often used. The synergistic effect of targeted drugs and radiotherapy in non-small cell lung cancer has shown good clinical efficacy. This article reviews the clinical progress of targeted drug therapy combined with radiotherapy in advanced non-small cell lung cancer in recent years, in order to provide new ideas for further clinical research of this treatment mode.

Keywords: monoclonal antibody; non-small cell lung cancer; targeted therapy; tyrosine kinase inhibitors; whole brain radiotherapy.

Publication types

Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.